Pfizer: A Conservative Valuation Leaves Room For A Post-LOE Re-Rating

Summary Pfizer remains a Buy, with valuation reflecting LOE risks and attractive risk-reward as the company executes on post-LOE growth strategies. PFE delivered a strong quarter, raising revenue guidance to $61.5B, driven by non-COVID portfolio strength and past acquisitions. Operational efficiency programs target $9.7B in cost savings through 2029, supporting ongoing R&D investment, deleveraging, and a robust 6.22% dividend yield. Intrinsic value for PFE is estimated above the current price, with upside potential if pipeline and cost initiatives deliver and a solid dividend paid in the meantime. VIDOK/iStock Unreleased via Getty Images Introduction In my previous Pfizer Inc. ( PFE ) analysis, I reiterated its Buy rating, highlighting the company's solid fundamentals as it was bracing for the LOE (loss of exclusivity) cliff through several aggressive acquisitions and a powerhouse This article was written by IWA Research 3.63K Followers Follow I've been researching companies in-depth for over a decade, from commodities like oil, natural gas, gold and copper to tech like Google or Nokia and many emerging market stocks, which I believe could help me provide useful content for readers. After writing my own blog for about 3 years, I decided to switch to a value investing-focused YouTube channel, where I researched hundreds of different companies so far. I would say my favorite type of company to cover are metals and mining stocks, but I am comfortable with several other industries, such as consumer discretionary/staples, REITs and utilities. Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in PFE over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.